News

Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth
Discover how Cytosorbents Corporation achieved 9% Q2 sales growth and navigates regulatory challenges for DrugSorb ATR.
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Cytosorbents Corporation ( NASDAQ: CTSO) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Peter J. Mariani - Chief Financial Officer Phillip P. Chan - CEO & Director Michael Anthony Sarcone ...